$BNTC $CVAC BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

Each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares

investors.biontech.de/news-release...

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Dis... – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high...

$TRML Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

www.globenewswire.com/news-release...

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug...

$CYTK Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

DEC 26, 2025

www.globenewswire.com/news-release...

Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and...

$RHHBY Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

www.roche.com/investors/up...

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69%...

$VERV Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

www.globenewswire.com/news-release...

Soleno Therapeutics Announces VYKAT(TM) XR Launch First prescriptions delivered to individuals with PWS...

$SLNO Soleno Therapeutics Announces VYKAT(TM) XR Launch

First prescriptions delivered to individuals with PWS

www.globenewswire.com/news-release...

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastroin...

$IRWD Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed

Co exploring strategic alternatives

www.businesswire.com/news/home/20...

$THRD Third Harmonic Bio Announces Plan of Liquidation and Dissolution

Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock

www.globenewswire.com/news-release...

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) recepto...

$PFE Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

Discontinue development of danuglipron (PF-06882961)

www.businesswire.com/news/home/20...

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity -- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at...

$RYTM Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

www.globenewswire.com/news-release...

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM

$SGMO Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

$18m upfront

www.businesswire.com/news/home/20...

$MLTX MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

ir.moonlaketx.com/news-release...

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery...

$NRIX Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Target different from STAT6

www.globenewswire.com/news-release...

(2/2) And those that are slated for "Mid-2025"

$FULC $LXEO $MLTX $MTSR $SMMT

(1/2) Well surely 2Q25 can't be worse than this, right? Here are some catalysts for 2Q25. Some that I'm watching are highlighted in peach!

Let me know if I missed your favorite

$APGE $CDTX $CELC $CRVS $KALA $KYMR $LLY $NKTR $RCKT $RYTM $RZLT $SRRK $TRML $VERA $VERV $VIGL

Peter Marks, FDA’s top vaccine regulator, forced out Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.

Our story on Marks’s ouster has been updated with a lot of comment and context www.statnews.com/2025/03/28/f...

Opthea Announces COAST Phase 3 Trial Topline Results COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial...

$OPT Opthea Announces COAST Phase 3 Trial Topline Results

Fail

www.globenewswire.com/news-release...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line...

$SKYE Moving up the obesity readout from 4Q25 -> Late 3Q/4Q25 due to faster-than-expected enrollment. No more interim, which was originally 2Q25

www.globenewswire.com/news-release...

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter...

$SNY Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

$600 million upfront and potential future payments totaling $1.3 billion

www.globenewswire.com/news-release...

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose...

$IMVT Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

www.globenewswire.com/news-release...

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and...

$BDTX Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Black Diamond will receive an upfront payment of $70 million and up to $710 million in milestones

www.globenewswire.com/news-release...

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as...

$ZEAL $RHHBY Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide for obesity

Zealand will receive upfront cash payments of $1.65B, and milestones for a total consideration of up to $5.3B

www.globenewswire.com/news-release...

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a

$IONS Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

www.businesswire.com/news/home/20...

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb 2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all

$TSVT 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

$5.00 per share, all-cash transaction

www.businesswire.com/news/home/20...

$PTGX Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

feeds.issuerdirect.com/news-release...

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension – Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg...

$MLYS Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

www.globenewswire.com/news-release...

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy...

$TRVI Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

57% placebo-adjusted change from baseline

ir.trevitherapeutics.com/2025-03-10-T...

$CKPT $FBIO In connection with the transaction, Checkpoint, Sun Pharma and Fortress Biotech, Inc., Checkpoint's controlling stockholder, have entered into a royalty agreement

Sun Pharma to Acquire Checkpoint Therapeutics Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell...

$CKPT Sun Pharma to Acquire Checkpoint Therapeutics

Upfront cash payment of $4.10 per share of common stock + CVR

www.prnewswire.com/news-release...

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy --FDA assigns PDUFA target action date of August 31, 2025-- --If approved, deramiocel would be first therapy to treat Duchenne muscular…...

$CAPR Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

AUG 31, 2025

www.capricor.com/investors/ne...